An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
Immunotherapy with immune checkpoint inhibitors (ICI) is a new option of treatment in a growing range of neoplasms. In addition to an antitumor effect, ICI are associated with autoimmune reactions resulting in a wide spectrum of toxicities that have not been seen in patients receiving chemotherapy....
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2020/4196178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560703570968576 |
|---|---|
| author | Kinga Krukowska Robert Kieszko Katarzyna Kurek Izabela Chmielewska Paweł Krawczyk Janusz Milanowski |
| author_facet | Kinga Krukowska Robert Kieszko Katarzyna Kurek Izabela Chmielewska Paweł Krawczyk Janusz Milanowski |
| author_sort | Kinga Krukowska |
| collection | DOAJ |
| description | Immunotherapy with immune checkpoint inhibitors (ICI) is a new option of treatment in a growing range of neoplasms. In addition to an antitumor effect, ICI are associated with autoimmune reactions resulting in a wide spectrum of toxicities that have not been seen in patients receiving chemotherapy. In this article, we present a case of a patient with advanced lung adenocarcinoma who developed an EDTA-dependent pseudothrombocytopenia (PTCP) during pembrolizumab therapy. To the best of our knowledge, this is the first reported case of EDTA-dependent PTCP occurring during immunotherapy treatment of nonsmall lung cell cancer with ICI. The phenomenon of EDTA-dependent PTCP may prompt clinical decisions, as unnecessary transfusions or even exclusion from pembrolizumab therapy. Therefore, it is important to be aware of PTCP as a possible side effect of this therapy. |
| format | Article |
| id | doaj-art-e1eca237ffaf4592b2a1cea3296653a8 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-e1eca237ffaf4592b2a1cea3296653a82025-02-03T01:27:04ZengWileyCase Reports in Oncological Medicine2090-67062090-67142020-01-01202010.1155/2020/41961784196178An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC PatientKinga Krukowska0Robert Kieszko1Katarzyna Kurek2Izabela Chmielewska3Paweł Krawczyk4Janusz Milanowski5Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, PolandImmunotherapy with immune checkpoint inhibitors (ICI) is a new option of treatment in a growing range of neoplasms. In addition to an antitumor effect, ICI are associated with autoimmune reactions resulting in a wide spectrum of toxicities that have not been seen in patients receiving chemotherapy. In this article, we present a case of a patient with advanced lung adenocarcinoma who developed an EDTA-dependent pseudothrombocytopenia (PTCP) during pembrolizumab therapy. To the best of our knowledge, this is the first reported case of EDTA-dependent PTCP occurring during immunotherapy treatment of nonsmall lung cell cancer with ICI. The phenomenon of EDTA-dependent PTCP may prompt clinical decisions, as unnecessary transfusions or even exclusion from pembrolizumab therapy. Therefore, it is important to be aware of PTCP as a possible side effect of this therapy.http://dx.doi.org/10.1155/2020/4196178 |
| spellingShingle | Kinga Krukowska Robert Kieszko Katarzyna Kurek Izabela Chmielewska Paweł Krawczyk Janusz Milanowski An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient Case Reports in Oncological Medicine |
| title | An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient |
| title_full | An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient |
| title_fullStr | An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient |
| title_full_unstemmed | An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient |
| title_short | An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient |
| title_sort | episode of pseudothrombocytopenia during pembrolizumab therapy in nsclc patient |
| url | http://dx.doi.org/10.1155/2020/4196178 |
| work_keys_str_mv | AT kingakrukowska anepisodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT robertkieszko anepisodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT katarzynakurek anepisodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT izabelachmielewska anepisodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT pawełkrawczyk anepisodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT januszmilanowski anepisodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT kingakrukowska episodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT robertkieszko episodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT katarzynakurek episodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT izabelachmielewska episodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT pawełkrawczyk episodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient AT januszmilanowski episodeofpseudothrombocytopeniaduringpembrolizumabtherapyinnsclcpatient |